title: Heterogeneity of epidemic Kaposi's sarcoma. Implications for therapy.
abstract: Kaposi's sarcoma (KS) in acquired immune deficiency syndrome (AIDS) is a new manifestation of a previously rare disease, and generally has a fatal course. Variations in the clinical course and in response to treatment by patients with this disease suggest that specific immunologic or clinical parameters may be important in the prognosis. Retrospective analyses of clinical parameters with respect to survival in 96 patients with epidemic Kaposi's sarcoma indicated that earlier tumor stage, the lack of prior opportunistic infections, and the absence of systemic symptoms correlated most closely with survival. Sixteen immune parameters were also assessed for their prognostic value. Total T4 (CD-4) cell number levels and the T4: T8 ratio correlated most closely with survival. Response to treatment with recombinant alpha interferons, while not well correlated with tumor stage, was more frequent in patients without systemic symptoms or a history or prior opportunistic infections. Treatment response was associated with a greater degree of intact T-cell function. These findings emphasize the importance of cellular immunity in the pathogenesis and subsequent course of patients with epidemic Kaposi's sarcoma, suggesting that different therapeutic strategies may be necessary to address specific prognostic subgroups.
authors.forename: R T
authors.initials: RT
authors.lastname: Mitsuyasu
authors.forename: J M
authors.initials: JM
authors.lastname: Taylor
authors.forename: J
authors.initials: J
authors.lastname: Glaspy
authors.forename: J L
authors.initials: JL
authors.lastname: Fahey
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000150:complications*; D000936:Antigen-Antibody Complex / Q000032:analysis; D000945:Antigens, Differentiation, T-Lymphocyte; D000954:Antigens, Surface / Q000032:analysis; D006801:Humans; D007070:Immunoglobulin A / Q000032:analysis; D007370:Interferon Type I / Q000627:therapeutic use; D007958:Leukocyte Count; D008213:Lymphocyte Activation; D011379:Prognosis; D011994:Recombinant Proteins / Q000627:therapeutic use; D012514:Sarcoma, Kaposi / Q000209:etiology / Q000276:immunology* / Q000628:therapy; D013601:T-Lymphocytes / Q000276:immunology
chemical_list: D000936:Antigen-Antibody Complex; D000945:Antigens, Differentiation, T-Lymphocyte; D000954:Antigens, Surface; D007070:Immunoglobulin A; D007370:Interferon Type I; D011994:Recombinant Proteins